D. Adamo

Cutaneous manifestations of taxol® therapy

E. Kohn, M. Christian, C. Link, 2004, Investigational New Drugs.

Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer

S. Steinberg, E. Kohn, R. Ozols, 1998, Cancer.

Age does not influence taxol dose intensity in recurrent carcinoma of the ovary

E. Kohn, B. Chabner, E. Reed, 2010, Cancer.

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.

F. Ognibene, E. Kohn, E. Reed, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy.

E. Kohn, M. Christian, C. Link, 1994, Blood.

Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.

F. Ognibene, S. Steinberg, E. Kohn, 1994, Journal of the National Cancer Institute.

Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma.

A. Foli, S. Broder, R. Yarchoan, 1993, Journal of the National Cancer Institute.

The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose‐intense taxol and granulocyte colony stimulating factor

E. Kohn, M. Christian, E. Reed, 1993, Anti-cancer drugs.